Functional localisation and scintigraphy in neuroendocrine tumours of the gastrointestinal tract and pancreas (GEP-NETs)

European Journal of Endocrinology

Volumn 170, Issue 5, 2014, Pages

  De Herder, Wouter W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; 6 FLUORODOPA F 18; CARBON 5 HYDROXYTRYPTOPHAN C 11; CHOLECYSTOKININ B RECEPTOR; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; IODINE VASOACTIVE INTESTINAL POLYPEPTIDE I 123; SOMATOSTATIN RECEPTOR; TETRAXETAN; TRACER; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

CANCER SCINTISCANNING; DIAGNOSTIC IMAGING; ECTOPIC CORTICOTROPIN PRODUCTION; GASTRINOMA; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; GASTROINTESTINAL TRACT SCINTISCANNING; HUMAN; IMAGE DISPLAY; INSULINOMA; INTERMETHOD COMPARISON; ISOTOPE LABELING; MOLECULAR IMAGING; PANCREAS SCINTISCANNING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; TUMOR BIOPSY; TUMOR LOCALIZATION; GASTROINTESTINAL TRACT; GASTROINTESTINAL TUMOR; METABOLISM; NEUROENDOCRINE TUMOR; PANCREAS; PANCREAS TUMOR; PERSONALIZED MEDICINE; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; WHOLE BODY IMAGING;

GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL TRACT; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR IMAGING; NEUROENDOCRINE TUMORS; PANCREAS; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIONUCLIDE IMAGING; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; WHOLE BODY IMAGING;

EID: 84899757452     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-14-0077     Document Type: Review

References (99)

1. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP et al. Gastroenteropancreatic neuroendocrine tumours Lancet. Oncology 2008 9 61-72. (doi:10.1016/S1470- 2045(07)70410-2
2. Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJ, van Eijck CH, Valkema R, de Jong M, de Herder WW & Krenning EP. Somatostatinreceptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocrine-Related Cancer 2010 17 R53-R73. (doi:10.1677/ERC-09-0078
3. Kaltsas GA, Besser GM & Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocrine Reviews 2004 25 458-511. (doi:10.1210/er.2003-0014
4. Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Archiv 2006 449 395-401. (doi:10.1007/s00428-006-0250-1
5. Rindi G, Kloppel G, Couvelard A, Komminoth P, Korner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Archiv 2007 451 757-762. (doi:10.1007/s00428-007-0452-1
6. Pape UF, Jann H, Muller-Nordhorn J, Bockelbrink A, Berndt U, Willich SN, Koch M, Rocken C, Rindi G & Wiedenmann B. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 2008 113 256-265. (doi:10.1002/cncr.23549
7. Velayoudom-Cephise FL, Duvillard P, Foucan L, Hadoux J, Chougnet CN, Leboulleux S, Malka D, Guigay J, Goere D, Debaere T et al. Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endocrine-Related Cancer 2013 20 649-657. (doi:10.1530/ERC-13-0027
8. Araujo PB, Cheng S, Mete O, Serra S, Morin E, Asa SL & Ezzat S. Evaluation of the WHO 2010 grading and AJCC/UICC staging systems in prognostic behavior of intestinal neuroendocrine tumors. PLoS ONE 2013 8 e61538. (doi:10.1371/journal.pone.0061538
9. Khan MS, Luong TV, Watkins J, Toumpanakis C, Caplin ME & Meyer T. A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms. British Journal of Cancer 2013 108 1838-1845. (doi:10.1038/bjc.2013.156
10. Rindi G, Falconi M, Klersy C, Albarello L, Boninsegna L, Buchler MW, Capella C, Caplin M, Couvelard A, Doglioni C et al. TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. Journal of the National Cancer Institute 2012 104 764-777. (doi:10.1093/jnci/djs208
11. Strosberg JR, Cheema A, Weber JM, Ghayouri M, Han G, Hodul PJ & Kvols LK. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications. Annals of Surgery 2012 256 321-325. (doi:10.1097/SLA. 0b013e31824e6108
12. Sundin A, Vullierme MP, Kaltsas G & Plockinger U. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological examinations. Neuroendocrinology 2009 90 167-183. (doi:10.1159/000184855
13. Sundin A. Radiological and nuclear medicine imaging of gastroenteropancreatic neuroendocrine tumours. Best Practice & Research. Clinical Obstetrics&Gynaecology201226803-818. (doi:10.1016/j.bpg.2012.12.004
14. de Herder WW, Hofland LJ, van der Lely AJ & Lamberts SW. Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. Endocrine-Related Cancer 2003 10 451-458. (doi:10.1677/erc. 0.0100451
15. Veenstra MJ, de Herder WW, Feelders RA & Hofland LJ. Targeting the somatostatin receptor in pituitary and neuroendocrine tumors. Expert Opinion on Therapeutic Targets 2013 17 1329-1343. (doi:10.1517/14728222.2013.830711
16. de Herder WW & Lamberts SW. Somatostatin analog therapy in treatment of gastrointestinal disorders and tumors. Endocrine 2003 20 285-290. (doi:10.1385/ENDO:20:3:285
17. de Herder WW, Kwekkeboom DJ, Feelders RA, van Aken MO, Lamberts SW, van der Lely AJ & Krenning EP. Somatostatin receptor imaging for neuroendocrine tumors. Pituitary 2006 9 243-248. (doi:10.1007/s11102-006-0270-5
18. Balon HR, Goldsmith SJ, Siegel BA, Silberstein EB, Krenning EP, Lang O & Donohoe KJ. Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide. Journal of Nuclear Medicine 2001 42 1134-1138.
19. Kwekkeboom DJ, Krenning EP, Scheidhauer K, Lewington V, Lebtahi R, Grossman A, Vitek P, Sundin A & Plockinger U. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: somatostatin receptor imaging with (111)In-pentetreotide. Neuroendocrinology 2009 90 184-189. (doi:10.1159/000225946
20. Oberg K, Kvols L, Caplin M, Delle Fave G, de Herder W, Rindi G, Ruszniewski P, Woltering EA & Wiedenmann B. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Annals of Oncology 2004 15 966-973. (doi:10.1093/annonc/mdh216
21. Lamberts SW, van der Lely AJ, de HerderWW& Hofland LJ. Octreotide. New England Journal of Medicine 1996 334 246-254. (doi:10.1056/ NEJM199601253340408
22. Zaknun JJ, Bodei L, Mueller-Brand J, Pavel ME, Baum RP, Horsch D, O'Dorisio MS, O'Dorisiol TM, Howe JR, Cremonesi M et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging 2013 40 800-816. (doi:10.1007/s00259-012-2330-6
23. Kwekkeboom DJ, Krenning EP, Lebtahi R, Komminoth P, Kos-Kudla B, de Herder WW & Plockinger U. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology 2009 90 220-226. (doi:10.1159/000225951
24. de Herder WW, Niederle B, Scoazec JY, Pauwels S, Kloppel G, Falconi M, Kwekkeboom DJ, Oberg K, Eriksson B, Wiedenmann B et al. Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology 2006 84 183-188. (doi:10.1159/000098010
25. Binderup T, Knigge U, Loft A, Mortensen J, Pfeifer A, Federspiel B, Hansen CP, Hojgaard L & Kjaer A. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET. Journal of Nuclear Medicine 2010 51 704-712. (doi:10.2967/jnumed.109.069765
26. Shah T, Kulakiene I, Quigley AM, Warbey VS, Srirajaskanthan R, Toumpanakis C, Hochhauser D, Buscombe J & Caplin ME. The role of 99mTc-depreotide in the management of neuroendocrine tumours. Nuclear Medicine Communications 2008 29 436-440. (doi:10.1097/MNM.0b013e3282f50747
27. Heppeler A, Froidevaux S, Eberle AN & Maecke HR. Receptor targeting for tumor localisation and therapy with radiopeptides. Current Medicinal Chemistry 2000 7 971-994. (doi:10.2174/0929867003374516
28. Smith-Jones PM, Bischof C, Leimer M, Gludovacz D, Angelberger P, Pangerl T, Peck-Radosavljevic M, Hamilton G, Kaserer K, Kofler A et al. DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy. Endocrinology 1999 140 5136-5148.
29. Cwikla JB, Mikolajczak R, Pawlak D, Buscombe JR, Nasierowska-Guttmejer A, Bator A, Maecke HR & Walecki J. Initial direct comparison of 99mTc-TOC and 99mTc-TATE in identifying sites of disease in patients with proven GEP NETs. Journal of Nuclear Medicine 2008 49 1060-1065. (doi:10.2967/jnumed.107.046961
30. Gabriel M, Muehllechner P, Decristoforo C, von Guggenberg E, Kendler D, Prommegger R, Profanter C, Moncayo R & Virgolini I. 99mTc-EDDA/HYNIC-Tyr(3)- octreotide for staging and follow-up of patients with neuroendocrine gastro-entero-pancreatic tumors. Quarterly Journal of Nuclear Medicine and Molecular Imaging 2005 49 237-244.
31. Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC & CaplinME. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. Journal of Nuclear Medicine 2013 54 364-372. (doi:10.2967/jnumed.112.111724
32. Haug AR, Cindea-Drimus R, Auernhammer CJ, Reincke M, Wangler B, Uebleis C, Schmidt GP, Goke B, Bartenstein P & Hacker M. The role of 68Ga-DOTATATE PET/CT in suspected neuroendocrine tumors. Journal of Nuclear Medicine 2012 53 1686-1692. (doi:10.2967/jnumed. 111.101675
33. Schraml C, Schwenzer NF, Sperling O, Aschoff P, Lichy MP, Muller M, Brendle C, Werner MK, Claussen CD & Pfannenberg C. Staging of neuroendocrine tumours: comparison of (68Ga)DOTATOC multiphase PET/CT and whole-body MRI. Cancer Imaging 2013 13 63-72. (doi:10.1102/1470-7330.2013.0007
34. Ambrosini V, Campana D, Nanni C, Cambioli S, Tomassetti P, Rubello D & Fanti S. Is 68Ga-DOTA-NOC PET/CT indicated in patients with clinical, biochemical or radiological suspicion of neuroendocrine tumour? European Journal of NuclearMedicine and Molecular Imaging 2012 39 1278-1283. (doi:10.1007/s00259-012-2146-4
35. Bombardieri E, Aktolun C, Baum RP, Bishof-Delaloye A, Buscombe J, Chatal JF, Maffioli L, Moncayo R, Mortelmans L & Reske SN. 131I/123I- metaiodobenzylguanidine (MIBG), scintigraphy: procedure guidelines for tumour imaging. European Journal of Nuclear Medicine and Molecular Imaging 2003 30 BP132-BP139.
36. Jacobson AF, Deng H, Lombard J, Lessig HJ & Black RR. 123I-metaiodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysis. Journal of Clinical Endocrinology and Metabolism 2010 95 2596-2606. (doi:10.1210/jc.2009-2604
37. Kaltsas G, Korbonits M, Heintz E, Mukherjee JJ, Jenkins PJ, Chew SL, Reznek R, Monson JP, Besser GM, Foley R et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. Journal of Clinical Endocrinology and Metabolism 2001 86 895-902. (doi:10.1210/jcem.86.2.7194
38. Kaltsas G, Rockall A, Papadogias D, Reznek R & Grossman AB. Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. European Journal of Endocrinology 2004 151 15-27. (doi:10.1530/eje.0. 1510015
39. Buscombe JR, Cwikla JB, Caplin ME & Hilson AJ. Long-term efficacy of low activity meta-(131I)iodobenzylguanidine therapy in patients with disseminated neuroendocrine tumours depends on initial response. Nuclear Medicine Communications 2005 26 969-976. (doi:10.1097/01.mnm.0000184941.06123.b9
40. Taal BG, Zuetenhorst H, Valdes Olmos RA & Hoefnagel CA. (131I)MIBG radionuclide therapy in carcinoid syndrome. European Journal of Surgical Oncology 2002 28 243. (doi:10.1053/ejso.2001.1225
41. Rufini V, Baum RP, Castaldi P, Treglia G, De Gaetano AM, Carreras C, Kaemmerer D, Hommann M, Horsch D, Bonomo L et al. Role of PET/CT in the functional imaging of endocrine pancreatic tumors. Abdominal Imaging 2012 37 1004-1020. (doi:10.1007/s00261-012-9871-9
42. Naswa N, Sharma P, Gupta SK, Karunanithi S, Reddy RM, Patnecha M, Lata S, Kumar R, Malhotra A & Bal C. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTANOC PET-CT and 18F-FDG PET-CT: competitive or complimentary? Clinical Nuclear Medicine 2014 39 e27-e34. (doi:10.1097/RLU. 0b013e31827a216b
43. Binderup T, Knigge U, Loft A, Federspiel B & Kjaer A. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clinical Cancer Research 2010 16 978-985. (doi:10.1158/1078-0432.CCR-09-1759
44. Abgral R, Leboulleux S, Deandreis D, Auperin A, Lumbroso J, Dromain C, Duvillard P, Elias D, de Baere T, Guigay J et al. Performance of (18) fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki67 (R10%) welldifferentiated endocrine carcinoma staging. Journal of Clinical Endocrinology and Metabolism 2011 96 665-671. (doi:10.1210/jc.2010-2022
45. Severi S, Nanni O, Bodei L, Sansovini M, Ianniello A, Nicoletti S, Scarpi E, Matteucci F, Gilardi L & Paganelli G. Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging 2013 40 881-888. (doi:10.1007/s00259-013-2369-z
46. van Essen M, Sundin A, Krenning EP&KwekkeboomDJ. Neuroendocrine tumours: the role of imaging for diagnosis and therapy. Nature Reviews. Endocrinology 2014 10 102-114. (doi:10.1038/nrendo.2013.246
47. Fiebrich HB, de Jong JR, Kema IP, Koopmans KP, Sluiter W, Dierckx RA, Walenkamp AM, Links TP, Brouwers AH & de Vries EG. Total 18F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour. European Journal of Nuclear Medicine and Molecular Imaging 2011 38 1854-1861. (doi:10.1007/s00259-011-1862-5
48. Zani A, Nah SA, Ron O, Totonelli G, Ismail D, Smith VV, Ashworth M, Blankenstein O, Mohnike W, De Coppi P et al. The predictive value of preoperative fluorine-18-L-3,4-dihydroxyphenylalanine positron emission tomography-computed tomography scans in children with congenital hyperinsulinism of infancy. Journal of Pediatric Surgery 2011 46 204-208. (doi:10.1016/j. jpedsurg.2010.09.093
49. MohnikeW,BarthlenW,MohnikeK&BlankensteinO.Positronemission tomography/computed tomography diagnostics by means of fluorine-18-L- dihydroxyphenylalanine in congenital hyperinsulinism. Seminars in Pediatric Surgery 2011 20 23-27. (doi:10.1053/j.sempedsurg.2010.10.007
50. Ismail D, Smith VV, de Lonlay P, Ribeiro MJ, Rahier J, Blankenstein O, Flanagan SE, Bellanne-Chantelot C, Verkarre V, Aigrain Y et al. Familial focal congenital hyperinsulinism. Journal of Clinical Endocrinology and Metabolism 2011 96 24-28. (doi:10.1210/jc.2010-1524
51. Ismail D, Kapoor RR, Smith VV, Ashworth M, Blankenstein O, Pierro A, Flanagan SE, Ellard S & Hussain K. The heterogeneity of focal forms of congenital hyperinsulinism. Journal of Clinical Endocrinology and Metabolism 2012 97 E94-E99. (doi:10.1210/jc.2011-1628
52. Barthlen W, Blankenstein O, Mau H, Koch M, Hohne C, Mohnike W, Eberhard T, Fuechtner F, Lorenz-Depiereux B & Mohnike K. Evaluation of (18F)fluoro-L-DOPA positron emission tomography-computed tomography for surgery in focal congenital hyperinsulinism. Journal of Clinical Endocrinology and Metabolism 2008 93 869-875. (doi:10.1210/jc.2007-2036
53. Orlefors H, Sundin A, Ahlstrom H, Bjurling P, Bergstrom M, Lilja A, Langstrom B, Oberg K & Eriksson B. Positron emission tomography with 5-hydroxytryptophan in neuroendocrine tumors. Journal of Clinical Oncology 1998 16 2534-2541.
54. Orlefors H, Sundin A, Garske U, Juhlin C, Oberg K, Langstrom B, Bergstrom M & Eriksson B. Whole-body 11C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors - comparison with somatostatin receptor scintigraphy and computed tomography. Journal of Clinical Endocrinology and Metabolism 2005 90 3392-3400. (doi:10.1210/jc.2004-1938
55. Froberg AC, de Jong M, Nock BA, Breeman WA, Erion JL, Maina T, Verdijsseldonck M, de Herder WW, van der Lugt A, Kooij PP et al. Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging 2009 36 1265-1272. (doi:10.1007/s00259-009-1098-9
56. Gotthardt M, Behe MP, Beuter D, Battmann A, Bauhofer A, Schurrat T, Schipper M, Pollum H, OyenWJ & Behr TM. Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging 2006 33 1273-1279. (doi:10.1007/s00259-006-0157-8
57. Nock BA, Maina T, Behe M, Nikolopoulou A, Gotthardt M, Schmitt JS, Behr TM & Macke HR. CCK-2/gastrin receptor-targeted tumor imaging with (99m)Tc-labeled minigastrin analogs. Journal of Nuclear Medicine 2005 46 1727-1736.
58. Kwekkeboom DJ, Reubi JC, Lamberts SW, Bruining HA, Mulder AH, Oei HY & Krenning EP. In vivo somatostatin receptor imaging in medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 1993 76 1413-1417.
59. Gotthardt M, Behe MP, Grass J, Bauhofer A, Rinke A, Schipper ML, Kalinowski M, Arnold R, Oyen WJ & Behr TM. Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours. Endocrine-Related Cancer 2006 13 1203-1211. (doi:10.1677/erc.1.01245
60. Wild D, Christ E, Caplin ME, Kurzawinski TR, Forrer F, Brandle M, Seufert J, Weber WA, Bomanji J, Perren A et al. Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. Journal of Nuclear Medicine 2011 52 1073-1078. (doi:10.2967/jnumed. 110.085142
61. Vezzosi D, Bennet A, Courbon F & Caron P. Short-and long-term somatostatin analogue treatment in patients with hypoglycaemia related to endogenous hyperinsulinism. Clinical Endocrinology 2008 68 904-911. (doi:10.1111/j.1365-2265.2007.03136.x
62. Vezzosi D, Bennet A, Rochaix P, Courbon F, Selves J, Pradere B, Buscail L, Susini C & Caron P. Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies. European Journal of Endocrinology 2005 152 757-767. (doi:10.1530/eje.1.01901
63. van Schaik E, van Vliet EI, Feelders RA, Krenning EP, Khan S, Kamp K, Valkema R, van Nederveen FH, Teunissen JJ, Kwekkeboom DJ et al. Improved control of severe hypoglycemia in patients with malignant insulinomas by peptide receptor radionuclide therapy. Journal of Clinical Endocrinology and Metabolism 2011 96 3381-3389. (doi:10.1210/jc.2011-1563
64. de HerderWW, van Schaik E, Kwekkeboom D & Feelders RA. New therapeutic options for metastatic malignant insulinomas. Clinical Endocrinology 2011 75 277-284. (doi:10.1111/j.1365-2265.2011.04145.x
65. Bertherat J, Tenenbaum F, Perlemoine K, Videau C, Alberini JL, Richard B, Dousset B, Bertagna X & Epelbaum J. Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study. Journal of Clinical Endocrinology and Metabolism 2003 88 5353-5360. (doi:10.1210/jc.2002-021895
66. Portela-Gomes GM, Stridsberg M, Grimelius L, Rorstad O & Janson ET. Differential expression of the five somatostatin receptor subtypes in human benign and malignant insulinomas - predominance of receptor subtype 4. Endocrine Pathology 2007 18 79-85. (doi:10.1007/s12022-007-0014-8
67. Wild D, Macke H, Christ E, Gloor B & Reubi JC. Glucagon-like peptide 1-receptor scans to localize occult insulinomas. New England Journal of Medicine 2008 359 766-768. (doi:10.1056/NEJMc0802045
68. Christ E, Wild D, Forrer F, Brandle M, Sahli R, Clerici T, Gloor B, Martius F, Maecke H & Reubi JC. Glucagon-like peptide-1 receptor imaging for localization of insulinomas. Journal of Clinical Endocrinology and Metabolism 2009 94 4398-4405. (doi:10.1210/jc.2009-1082
69. Christ E, Wild D, Ederer S, Behe M, Nicolas G, Caplin ME, Brandle M, Clerici T, Fischli S, Stettler C et al. Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study. Lancet. Diabetes & Endocrinology 2013 1 115-122. (doi:10.1016/S2213-8587(13) 70049-4
70. Grossman A. The nuclear option for insulinomas. Lancet. Diabetes & Endocrinology 2013 1 82-84. (doi:10.1016/S2213-8587(13)70060-3
71. Pach D, Sowa-Staszczak A, Jabrocka-Hybel A, Stefanska A, Tomaszuk M, Mikolajczak R, Janota B, Trofimiuk-Muldner M, Przybylik-Mazurek E & Hubalewska-Dydejczyk A. Glucagon-like peptide-1 receptor imaging with (Lys(40) (Ahx-HYNIC-(99m)Tc/EDDA)NH 2)-exendin-4 for the diagnosis of recurrence or dissemination of medullary thyroid cancer: a preliminary report. International Journal of Endocrinology 2013 2013 384508. (doi:10.1155/2013/384508
72. Sowa-Staszczak A, Pach D, Mikolajczak R, Macke H, Jabrocka-Hybel A, Stefanska A, Tomaszuk M, Janota B, Gilis-Januszewska A, Malecki M et al. Glucagon-like peptide-1 receptor imaging with (Lys40(Ahx-HYNIC-99mTc/EDDA)NH2)- exendin-4 for the detection of insulinoma. European Journal of Nuclear Medicine and Molecular Imaging 2013 40 524-531. (doi:10.1007/s00259-012-2299-1
73. Brom M, Oyen WJ, Joosten L, Gotthardt M & Boerman OC. 68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET. European Journal of Nuclear Medicine and Molecular Imaging 2010 37 1345-1355. (doi:10.1007/s00259-009-1363-y
74. Hessenius C, Bader M, Meinhold H, Bohmig M, Faiss S, Reubi JC & Wiedenmann B. Vasoactive intestinal peptide receptor scintigraphy in patients with pancreatic adenocarcinomas or neuroendocrine tumours. European Journal of Nuclear Medicine 2000 27 1684-1693. (doi:10.1007/s002590000325
75. Virgolini I, Kurtaran A, Leimer M, Kaserer K, Peck-Radosavljevic M, Angelberger P, Hubsch P, Dvorak M, Valent P & Niederle B. Location of a VIPoma by iodine-123-vasoactive intestinal peptide scintigraphy. Journal of Nuclear Medicine 1998 39 1575-1579.
76. Virgolini I, Raderer M, Kurtaran A, Angelberger P, Banyai S, Yang Q, Li S, Banyai M, Pidlich J, Niederle B et al. Vasoactive intestinal peptidereceptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. New England Journal of Medicine 1994 331 1116-1121. (doi:10.1056/ NEJM199410273311703
77. Druce MR, Muthuppalaniappan VM, O'Leary B, Chew SL, Drake WM, Monson JP, Akker SA, Besser M, Sahdev A, Rockall A et al. Diagnosis and localisation of insulinoma: the value of modern magnetic resonance imaging in conjunction with calcium stimulation catheterisation. European Journal of Endocrinology 2010 162 971-978. (doi:10.1530/EJE-10-0056
78. Doppman JL, Chang R, Fraker DL, Norton JA, Alexander HR, Miller DL, Collier E, Skarulis MC & Gorden P. Localization of insulinomas to regions of the pancreas by intra-arterial stimulation with calcium. Annals of Internal Medicine 1995 123 269-273. (doi:10.7326/0003-4819-123-4-199508150-00004
79. Doherty GM, Doppman JL, Shawker TH, Miller DL, Eastman RC, Gorden P & Norton JA. Results of a prospective strategy to diagnose, localize, and resect insulinomas. Surgery 1991 110 989-996.
80. Braatvedt G, Jennison E & Holdaway IM. Comparison of two low-dose calcium infusion schedules for localization of insulinomas by selective pancreatic arterial injection with hepatic venous sampling for insulin. Clinical Endocrinology 2014 80 80-84. (doi:10.1111/cen.12253
81. Lo CY, Chan FL, Tam SC, Cheng PW, Fan ST & Lam KS. Value of intraarterial calcium stimulated venous sampling for regionalization of pancreatic insulinomas. Surgery 2000 128 903-909. (doi:10.1067/msy.2000.109729
82. Gibril F, Reynolds JC, Doppman JL, Chen CC, Venzon DJ, Termanini B, Weber HC, Stewart CA & Jensen RT. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Annals of Internal Medicine 1996 125 26-34. (doi:10.7326/0003-4819-125-1-199607010-00005
83. Jensen RT & Gibril F. Somatostatin receptor scintigraphy in gastrinomas. Italian Journal of Gastroenterology and Hepatology 1999 31 (Suppl 2) S179-S185.
84. Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P, Scoazec JY, Salazar R, Sauvanet A & Kianmanesh R. ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology 2012 95 98-119. (doi:10.1159/000335591
85. Krenning EP, Kwekkeboom DJ, Oei HY, de Jong RJ, Dop FJ, de Herder WW, Reubi JC & Lamberts SW. Somatostatin receptor scintigraphy in carcinoids, gastrinomas and Cushing's syndrome. Digestion 1994 55 (Suppl 3) 54-59. (doi:10.1159/000201202
86. Jackson JE. Angiography and arterial stimulation venous sampling in the localization of pancreatic neuroendocrine tumours. Best Practice and Research. Clinical Endocrinology & Metabolism 2005 19 229-239. (doi:10.1016/j.beem. 2004.10.002
87. Cherner JA, Doppman JL, Norton JA, Miller DL, Krudy AG, Raufman JP, Collen MJ, Maton PN, Gardner JD & Jensen RT. Selective venous sampling for gastrin to localize gastrinomas. A prospective assessment. Annals of Internal Medicine 1986 105 841-847. (doi:10.7326/0003-4819-105-6-841
88. Doppman JL, Miller DL, Chang R, Maton PN, London JF, Gardner JD, Jensen RT & Norton JA. Gastrinomas: localization by means of selective intraarterial injection of secretin. Radiology 1990 174 25-29.
89. Isidori AM, Kaltsas GA, Pozza C, Frajese V, Newell-Price J, Reznek RH, Jenkins PJ, Monson JP, Grossman AB & Besser GM. The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up. Journal of Clinical Endocrinology and Metabolism 2006 91 371-377. (doi:10.1210/jc.2005-1542
90. de Herder WW, Uitterlinden P, Pieterman H, Tanghe HL, Kwekkeboom DJ, Pols HA, Singh R, van de Berge JH & Lamberts SW. Pituitary tumour localization in patients with Cushing's disease by magnetic resonance imaging. Is there a place for petrosal sinus sampling? Clinical Endocrinology 1994 40 87-92. (doi:10.1111/j.1365-2265.1994.tb02448.x
91. Lamberts SW, de Herder WW, Krenning EP & Reubi JC. A role of (labeled) somatostatin analogs in the differential diagnosis and treatment of Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 1994 78 17-19.
92. de Herder WW, Krenning EP, Malchoff CD, Hofland LJ, Reubi JC, Kwekkeboom DJ, Oei HY, Pols HA, Bruining HA & Nobels FR. Somatostatin receptor scintigraphy: its value in tumor localization in patients with Cushing's syndrome caused by ectopic corticotropin or corticotropin-releasing hormone secretion. American Journal of Medicine 1994 96 305-312. (doi:10.1016/0002- 9343(94)90059-0
93. Zemskova MS, Gundabolu B, Sinaii N, Chen CC, Carrasquillo JA, Whatley M, Chowdhury I, Gharib AM & Nieman LK. Utility of various functional and anatomic imaging modalities for detection of ectopic adrenocorticotropin- secreting tumors. Journal of Clinical Endocrinology and Metabolism 2010 95 1207-1219. (doi:10.1210/jc.2009-2282
94. Sugiyama M, Sugiyama T, Yamaguchi M, Izumiyama H, Yoshimoto T, Kishino M, Akashi T & Hirata Y. Successful localization of ectopic ACTH-secreting bronchial carcinoid by selective pulmonary arterial sampling. Endocrine Journal 2010 57 959-964. (doi:10.1507/endocrj.K10E-192
95. Sakuma I, Saito J, Matsuzawa Y, Omura M, Matsui S, Maehara T, Hasegawa N & Nishikawa T. Pulmonary arterial sampling was useful for localizing ectopic ACTH production in a patient with bronchial carcinoid causing Cushing syndrome. Hormones 2013 12 449-453.
96. Wang X, Fani M, Schulz S, Rivier J, Reubi JC & Maecke HR. Comprehensive evaluation of a somatostatin-based radiolabelled antagonist for diagnostic imaging and radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging 2012 39 1876-1885. (doi:10.1007/s00259-012-2231-8
97. Marsouvanidis PJ, Maina T, Sallegger W, Krenning EP, de Jong M & Nock BA. 99mTc radiotracers based on human GRP(18-27): synthesis and comparative evaluation. Journal of Nuclear Medicine 2013 54 1797-1803. (doi:10.2967/jnumed. 112.118695
98. Richter S, Wuest M, Krieger SS, Rogers BE, Friebe M, Bergmann R & Wuest F. Synthesis and radiopharmacological evaluation of a high-affinity and metabolically stabilized 18F-labeled bombesin analogue for molecular imaging of gastrin-releasing peptide receptor-expressing prostate cancer. Nuclear Medicine and Biology 2013 40 1025-1034. (doi:10.1016/j.nucmedbio.2013.07.005
99. Varasteh Z, Aberg O, Velikyan I, Lindeberg G, Sorensen J, Larhed M, Antoni G, Sandstrom M, Tolmachev V & Orlova A. In vitro and in vivo evaluation of a (18)F-labeled high affinity NOTA conjugated bombesin antagonist as a PET ligand for GRPR-targeted tumor imaging. PLoS ONE 2013 8 e81932. (doi:10.1371/journal.pone.0081932)